Relmada Therapeutics (RLMD) Misses Q4 EPS by 1c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.84), $0.01 worse than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
• BlackRock’s Rosenberg says inflation data key after jobs beat